Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label dose-ranging study of mitapivat in adults with pyruvate kinase deficiency
2015-000484-13Phase 2Unknown
- Sponsor
- Agios Pharmaceuticals
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mitapivat in pyruvate kinase deficiency (PKD) (2 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Safety and tolerability, Hormonal, bone, and lipid safety assessments and 1 more. Status: unknown.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on 2015-000484-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000484-13.